Price T Rowe Associates Inc. MD Has $79.64 Million Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Price T Rowe Associates Inc. MD reduced its holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 14.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,423,537 shares of the biopharmaceutical company's stock after selling 408,975 shares during the quarter. Price T Rowe Associates Inc. MD owned 4.25% of Agios Pharmaceuticals worth $79,639,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the business. Venturi Wealth Management LLC bought a new position in shares of Agios Pharmaceuticals in the fourth quarter valued at $33,000. Wingate Wealth Advisors Inc. purchased a new stake in shares of Agios Pharmaceuticals during the fourth quarter valued at $53,000. Sterling Capital Management LLC boosted its position in shares of Agios Pharmaceuticals by 818.0% in the 4th quarter. Sterling Capital Management LLC now owns 1,781 shares of the biopharmaceutical company's stock valued at $59,000 after purchasing an additional 1,587 shares during the period. KBC Group NV increased its stake in Agios Pharmaceuticals by 30.5% in the 4th quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company's stock worth $86,000 after purchasing an additional 611 shares in the last quarter. Finally, AlphaQuest LLC raised its holdings in Agios Pharmaceuticals by 106.2% during the 4th quarter. AlphaQuest LLC now owns 4,540 shares of the biopharmaceutical company's stock worth $149,000 after buying an additional 2,338 shares during the period.

Agios Pharmaceuticals Stock Down 2.7 %

Agios Pharmaceuticals stock traded down $0.84 during trading hours on Friday, hitting $30.10. The stock had a trading volume of 415,741 shares, compared to its average volume of 700,873. The company has a 50-day moving average of $29.81 and a two-hundred day moving average of $37.80. Agios Pharmaceuticals, Inc. has a fifty-two week low of $23.42 and a fifty-two week high of $62.58. The company has a market cap of $1.74 billion, a PE ratio of 2.65 and a beta of 0.83.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last issued its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($1.55) EPS for the quarter, beating analysts' consensus estimates of ($1.80) by $0.25. Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. As a group, analysts forecast that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current fiscal year.

Insider Transactions at Agios Pharmaceuticals

In related news, Director Jacqualyn A. Fouse sold 7,497 shares of the firm's stock in a transaction that occurred on Thursday, April 10th. The stock was sold at an average price of $25.90, for a total transaction of $194,172.30. Following the completion of the transaction, the director now owns 149,220 shares in the company, valued at $3,864,798. This trade represents a 4.78 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 4.93% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. Scotiabank dropped their target price on shares of Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating on the stock in a research report on Friday. StockNews.com upgraded shares of Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Thursday. Finally, HC Wainwright initiated coverage on Agios Pharmaceuticals in a research report on Monday, February 24th. They set a "buy" rating and a $58.00 price target on the stock. Five investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, Agios Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus target price of $56.00.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.